Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright
After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, ...
Dow Jones Today: Major Indexes Higher as Stock Market Rally Continues; Bitcoin Slips
Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...
MedPage Today1h
Thyroid Drug & Bone Loss; GLP-1s' Renal Benefit; Menopause Musculoskeletal Syndrome
The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...
New U.S. drug causes 20 pct weigh loss in early results: report
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose an average of up to 20 percent of th ...
Amgen shares fall on anti-obesity drug; rivals Novo and Lilly gain
STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
The Express Tribune1h
Amgen's experimental injection leads to 20% average weight loss in key trial
MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...
Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Pacbiztimes.com2h
Amgen’s shares down after obesity drug fails to meet expectations
MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...